Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

House Medicare Rx Bill Authorizes Tiered Co-Pays, De-Emphasizes Mail

Executive Summary

The draft House Republican Medicare prescription drug bill includes language explicitly authorizing tiered co-pays

You may also be interested in...



House Medicare Rx Bill Fits “Fundamental” PBM Model, Express Scripts Says

The House Republican Medicare Rx proposal would fit with Express Scripts' "fundamental" pharmacy benefit management model, the company reminded analysts during a June 18 investor day

House Medicare Rx Bill Fits “Fundamental” PBM Model, Express Scripts Says

The House Republican Medicare Rx proposal would fit with Express Scripts' "fundamental" pharmacy benefit management model, the company reminded analysts during a June 18 investor day

House Medicare Rx Bill Offers Juicier Reinsurance Bait; HIAA Bites

The House Republican Medicare drug benefit bill is wooing plan sponsors with a 35% direct subsidy plus a 30% reinsurance rate for additional costs

Related Content

UsernamePublicRestriction

Register

OM001644

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel